Hiroshi Takeyama1, Tsunekazu Mizushima2, Hideki Iijima3, Shinzaki Shinichiro3, Mamoru Uemura1, Junichi Nishimura1, Taishi Hata1, Ichiro Takemasa1, Hirofumi Yamamoto1, Yuichiro Doki1, Masaki Mori1. 1. Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka, 565-0871, Japan. 2. Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka, 565-0871, Japan. tmizushima@gesurg.med.osaka-u.ac.jp. 3. Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka, 565-0871, Japan.
Abstract
BACKGROUND: In assessing Crohn's disease (CD) activity, C-reactive protein (CRP) is an important indicator of inflammation; however, it is not necessarily associated with the Crohn's Disease Activity Index (CDAI), particularly in patients with low CRP. Recently, platelet activation factors have been recognized due to their importance in the inflammatory response. In this study, we examined associations between the CDAI and platelet factor 4 (PF-4), β-thromboglobulin (β-TG), and other coagulation and fibrinolysis factors. AIMS: We aimed to find a new marker for evaluating disease activity in patients with CD and low CRP. METHODS: Nine markers, including CRP, platelet count, white blood cell count, fibrin and fibrinogen degradation product, fibrinogen, thrombin-antithrombin complex, prothrombin fragments 1 + 2, PF-4, and β-TG were evaluated in 47 patients with CD and low CRP (<1.0 mg/dl). Patients were assigned to high or low disease activity groups, CDAI-H (CDAI ≥ 150) and CDAI-L (CDAI < 150), respectively. RESULTS: CDAI-H exhibited significantly higher PF-4 and β-TG levels than CDAI-L (P < 0.01). Other markers were not significantly different between groups. CDAI was positively correlated with the levels of PF-4 and β-TG (P = 0.0033 and 0.0024; r = 0.4202 and 0.4321, respectively). Receiver operating characteristic curve analyses of PF-4 and β-TG showed high sensitivity (61.9 and 81%, respectively) and specificity (84.7 and 69.2%, respectively) for diagnosing active CD. CONCLUSION: Among eight potential markers, PF-4 and β-TG were the most highly correlated with CDAI in patients with CD and low CRP. PF-4 and β-TG levels showed promise as new markers for assessing CD in patients with low CRP.
BACKGROUND: In assessing Crohn's disease (CD) activity, C-reactive protein (CRP) is an important indicator of inflammation; however, it is not necessarily associated with the Crohn's Disease Activity Index (CDAI), particularly in patients with low CRP. Recently, platelet activation factors have been recognized due to their importance in the inflammatory response. In this study, we examined associations between the CDAI and platelet factor 4 (PF-4), β-thromboglobulin (β-TG), and other coagulation and fibrinolysis factors. AIMS: We aimed to find a new marker for evaluating disease activity in patients with CD and low CRP. METHODS: Nine markers, including CRP, platelet count, white blood cell count, fibrin and fibrinogen degradation product, fibrinogen, thrombin-antithrombin complex, prothrombin fragments 1 + 2, PF-4, and β-TG were evaluated in 47 patients with CD and low CRP (<1.0 mg/dl). Patients were assigned to high or low disease activity groups, CDAI-H (CDAI ≥ 150) and CDAI-L (CDAI < 150), respectively. RESULTS:CDAI-H exhibited significantly higher PF-4 and β-TG levels than CDAI-L (P < 0.01). Other markers were not significantly different between groups. CDAI was positively correlated with the levels of PF-4 and β-TG (P = 0.0033 and 0.0024; r = 0.4202 and 0.4321, respectively). Receiver operating characteristic curve analyses of PF-4 and β-TG showed high sensitivity (61.9 and 81%, respectively) and specificity (84.7 and 69.2%, respectively) for diagnosing active CD. CONCLUSION: Among eight potential markers, PF-4 and β-TG were the most highly correlated with CDAI in patients with CD and low CRP. PF-4 and β-TG levels showed promise as new markers for assessing CD in patients with low CRP.
Authors: Jennifer Jones; Edward V Loftus; Remo Panaccione; Li-Sheng Chen; Sandra Peterson; Joseph McConnell; Linnea Baudhuin; Karen Hanson; Brian G Feagan; Scott W Harmsen; Alan R Zinsmeister; Emelie Helou; William J Sandborn Journal: Clin Gastroenterol Hepatol Date: 2008-09-17 Impact factor: 11.382
Authors: L S Kiss; T Szamosi; T Molnar; P Miheller; L Lakatos; A Vincze; K Palatka; Z Barta; B Gasztonyi; A Salamon; G Horvath; G T Tóth; K Farkas; J Banai; Z Tulassay; F Nagy; M Szenes; G Veres; B D Lovasz; Z Vegh; P A Golovics; M Szathmari; M Papp; P L Lakatos Journal: Aliment Pharmacol Ther Date: 2011-08-24 Impact factor: 8.171
Authors: Mumtaz Hayat; Robert A S Ariëns; Paul Moayyedi; Peter J Grant; Seamus O'Mahony Journal: Eur J Gastroenterol Hepatol Date: 2002-03 Impact factor: 2.566
Authors: W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek Journal: Gut Date: 2004-04 Impact factor: 23.059
Authors: Bruno Lima Rodrigues; Márcia Carolina Mazzaro; Cristiane Kibune Nagasako; Maria de Lourdes Setsuko Ayrizono; João José Fagundes; Raquel Franco Leal Journal: World J Gastrointest Endosc Date: 2020-12-16
Authors: Jean-Paul Motta; Simone Palese; Carmine Giorgio; Kevin Chapman; Alexandre Denadai-Souza; Perrine Rousset; David Sagnat; Laura Guiraud; Anissa Edir; Carine Seguy; Laurent Alric; Delphine Bonnet; Barbara Bournet; Louis Buscail; Cyrielle Gilletta; Andre G Buret; John L Wallace; Morley D Hollenberg; Eric Oswald; Elisabetta Barocelli; Sylvie Le Grand; Bruno Le Grand; Celine Deraison; Nathalie Vergnolle Journal: J Crohns Colitis Date: 2021-05-04 Impact factor: 9.071
Authors: Ryan W Stidham; Yumu Liu; Binu Enchakalody; Tony Van; Venkataramu Krishnamurthy; Grace L Su; Ji Zhu; Akbar K Waljee Journal: Inflamm Bowel Dis Date: 2021-07-27 Impact factor: 5.325